Navigation Links
OncoSec Medical Announces $7.2 Million Public Offering
Date:12/13/2012

SAN DIEGO, Dec. 13, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $7.2 million of securities in a registered public offering. OncoSec has agreed to sell to institutional investors an aggregate of 28,800,000 shares of its common stock at $0.25 per share. Additionally, investors will receive warrants to purchase up to 14,400,000 shares of common stock at an exercise price of $0.26 per share for a term of four years.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

The gross proceeds of the offering are expected to be approximately $7.2 million. Net proceeds, after deducting the placement agent's fee and other estimated offering expenses payable by OncoSec, are expected to be approximately $6.5 million.

OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses.

Dawson James Securities, Inc. acted as the exclusive placement agent for the transaction.  Burrill LLC and Noble Financial Capital Markets acted as financial advisors to OncoSec in connection with the transaction.

The offering is expected to close on December 17, 2012, subject to customary closing conditions.

The securities described above are being offered by OncoSec pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission, or the SEC. A prospectus supplement related to the offering will be filed with the SEC. The securities may only be offered by means of a prospectus. Copies of the prospectus and prospectus supplement can be obtained directly from OncoSec and at the
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
8. OncoSec Granted New Patent from China
9. OncoSec to Present at Upcoming Healthcare and Investor Conferences
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Cadence Fitness & Health Center has been certified ... Association, a non-profit organization assisting medically integrated health and ... Fitness & Health Center is the only certified fitness ... Chicagoland area. "The certification means the Cadence ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... Annual Meeting -, SAN FRANCISCO and EMERYVILLE, ... ) today announced results on the role of ... cancer and,osteoporosis. The data, which were presented at ... new regulatory elements are essential,for the differentiation of ...
... June 16 SuperGen Inc.,(Nasdaq: SUPG ... discovery, rapid,development and commercialization of therapies for ... the 13th Congress of the,European Hematology Association ... kinase inhibitor, prevents tumor cell proliferation in,vivo ...
Cached Medicine Technology:Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs 2Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs 3SuperGen's JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell Proliferation 2
(Date:4/18/2014)... Hopkins University School of Medicine researchers have been awarded ... diabetes, Novo Nordisk announced this month. Of the 110 ... Obesity Biologics Science Forum Program, only four projects were ... researchers. They are Jonathan Powell, M.D., Ph.D.; G. William ... Jonathan Powell, a professor of oncology, will use his ...
(Date:4/18/2014)... French . ... regenerative medicine. A team led by Ludwik Leibler from ... and Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle ... that the principle of adhesion by aqueous solutions of ... organs and tissues. This easy-to-use gluing method has been ...
(Date:4/17/2014)... have identified new pain relief targets that could ... BBSRC-funded researchers at King,s College London made the ... in the periphery of the body. , Dr ... identifying mechanisms underlying pain generation and our findings ... side effects." , One potential side effect of ...
(Date:4/17/2014)... 17, 2014) Two recent papers by a ... colleagues may help scientists develop treatments or vaccines ... Japanese encephalitis and other disease-causing flaviviruses. , Jeffrey ... molecular genetics at the School of Medicine and ... Medical Institute, and colleagues recently published articles in ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... BRUNSWICK, N.J., Dec. 8 Savient Pharmaceuticals, Inc. (Nasdaq: ... Pharmaceuticals will be presenting at the upcoming 27th Annual J.P. Morgan ... presentation is scheduled to begin on Wednesday, January 14, 2009 at ... Westin St. Francis Hotel in San Francisco, CAJanuary 11-15, 2009. , ...
... Haemonetics announced today that Dr. Jonathan White will ... President of Haemonetics, effective December 8, 2008. In this ... of the next generation of products to complement Haemonetics, blood ... Brad Nutter, Haemonetics, Chairman and CEO, said, "As the global ...
... of the two-story,$35-millionHenry Ford II (West) Pavilion expansion project ... to 40 new private rooms complete,with wireless Internet access, ... to stay overnight. , ... investment in the Henry Ford,Hospital Campus. It will house ...
... Dec. 8 With its acclaimed debut in ... paper,patient medical records by bringing the process into ... far beyond basic record-keeping, allowing,subscribers to take charge ... their,records to use under their own centralized control ...
... Dec. 8 Triple-S,Management Corporation (NYSE: GTS ... announced that it has converted seven million issued and,outstanding ... in,conjunction with the expiration of the lockup agreements signed ... the Company,s initial public offering. It is,expected that the ...
... New Year,s is the most popular,time to try quitting smoking, ... that time resume smoking in less than one week.(1) ... of a New Year,s resolution,and may be well on their ... that smokers who use the 21 mg NicoDerm(R) CQ(R) nicotine ...
Cached Medicine News:Health News:Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th 2Health News:Dr. Jonathan White Joins Haemonetics as Head of Research and Development 2Health News:$35 Million Henry Ford II Pavilion Expansion to Open 2Health News:$35 Million Henry Ford II Pavilion Expansion to Open 3Health News:$35 Million Henry Ford II Pavilion Expansion to Open 4Health News:MyHealthArchive.com's New Features -- A Quantum Leap in Using Health Information to Promote Your Health 2Health News:MyHealthArchive.com's New Features -- A Quantum Leap in Using Health Information to Promote Your Health 3Health News:MyHealthArchive.com's New Features -- A Quantum Leap in Using Health Information to Promote Your Health 4Health News:Triple-S Management Corporation Announces Conversion of Class A Shares and Commencement of Class B Stock Repurchase Program 2Health News:New Research May Encourage Smokers to Jump-Start Their New Year's Resolution to Quit Smoking 2Health News:New Research May Encourage Smokers to Jump-Start Their New Year's Resolution to Quit Smoking 3Health News:New Research May Encourage Smokers to Jump-Start Their New Year's Resolution to Quit Smoking 4
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... chairs with concave seats and ... • Select options like seats, ... glides. • BTT/1P chairs are ... industry, education, laboratory, clean room, ...
... Basic ergonomic chairs with ... with lumbar support • Select ... and casters and glides. • ... the following environments: industry, education, ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
Medicine Products: